Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Conference News NY Valves 2024

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Michael O'Riordan

June 12, 2024

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

L.A. McKeown

October 18, 2023

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

Advertisement

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

April 2025 Dispatch for the CV Team

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Polymer Mitral Valve Shows Well Early, but Long-term Data Key

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Most Patient-Reported Outcome Measures in CVD Fall Short

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Dapagliflozin Boosts Health Status Across LVEF Range

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content